Innovent licenses IBI355 rights to Spero for up to $1.1bn

PartnershipIBI355Positive

AI Analysis

Summary

Innovent Biologics has granted Spero Therapeutics an exclusive licence to develop and commercialise IBI355 outside Greater China, with potential deal value up to $1.1 billion.

Outcome Details

Exclusive licence deal for IBI355 development and commercialisation outside Greater China

Importance:7/10

Sentiment:

0.60

licensingpartnershipexclusive dealgeographic rights

Related Companies

$GCAN $CHHE

Read the original article

Published by Pharmaceutical Technology on July 15, 2026 9:01 AM

Read Original